CXA-101/Tazobactam

CXA-101/tazobactam · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CXA-101/Tazobactam, covering 2015-01-16 to 2017-01-26. Get the full timeline:

Most recent: Clinical Trial Update: Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects [Phase 1]

See pricing